Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03864627 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Lakefront Biotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03864627: Clinical Trial Phase 2 study, sponsored by Lakefront Biotherapeutics.
NCT03864627 is a Phase 2 study that was terminated before completion, run by Lakefront Biotherapeutics. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03864627, a Phase 2 study, was terminated before completion, sponsored by Lakefront Biotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Interventions
- DRUG Placebo
- DRUG MOR106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03864627
The ClinicalTrials.gov registry entry for NCT03864627 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03864627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03864627 about?
NCT03864627 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis". To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
What is the current status of trial NCT03864627?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-03-25. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03864627?
The interventions under investigation include: Placebo (DRUG), MOR106 (DRUG).
Who is sponsoring clinical trial NCT03864627?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.